Chemotherapy and other supportive modalities in the palliative setting for pancreatic cancer

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 633-641

  Sullivan, Kevin M ^a   Kozuch, Peter S ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

erlotinib; FOLFIRINOX; gemcitabine; Metastatic pancreatic cancer; palliative chemotherapy

Indexed keywords

CAPECITABINE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; SUNITINIB;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; DIARRHEA; FEBRILE NEUTROPENIA; HUMAN; INFECTION; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NUTRITIONAL SUPPORT; PANCREAS CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SENSORY NEUROPATHY; STOMATITIS; THROMBOCYTOPENIA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84871198188     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318275896f     Document Type: Review

References (64)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10.
2. Conroy T, Desseigne F, Ychou M, et al. Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for meta-static pancreatic adenocarcinoma (MPA): preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial. J Clin Oncol. 2010;28:15s, (suppl; abstr 4010).
3. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcita-bine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
4. Arlen AG, Cartwright TH, Wilfong LS, et al. Use of first-line chemotherapy for advanced pancreatic cancer: FOLFIRINOX versus gemcita-bine. J Clin Oncol. 2012;30:(suppl; abstr e16536).
5. Lowery MA, Yu KH, Adel NG, et al. Activity of front-line FOLFIRI-NOX (FFX) in stage III/IV pancreatic adenocarcinoma (PC) at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol. 2012;30: (suppl; abstr 4057).
6. Goncalves, PH, Ruch JM, Byer J, et al. Multi-institutional experience using 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRI-NOX) in patients with pancreatic cancer (PCA). J Clin Oncol. 2012; 30:(suppl; abstr e14519).
7. Gunturu KS, Thumar JR, Hochster HS, et al. Single institution experience with FOLFIRINOX in advanced pancreatic cancer (PC). J Clin Oncol. 2012;30:(suppl; abstr e14534).
8. Faris JE, Hong TS, McDermott S, et al. FOLFIRINOX in locally advanced and metastatic pancreatic cancer. J Clin Oncol. 2012;30:(suppl; abstr e14615).
9. Ko AH. FOLFIRINOX: a small step or a great leap forward? J Clin Oncol. 2011;29:3727-3729.
10. Gill S, Ho MY, Kennecke HF, et al. Defining eligibility of FOLFIRI-NOX for first-line metastatic pancreatic adenocarcinoma (MPC) in the province of British Columbia: a population-based retrospective study. J Clin Oncol. 2012;20:(suppl; abstr e14588).
11. Mahaseth H, Kauh JS, Brutcher E, et al. Safety and efficacy of modified FOLFIRINOX in pancreatic cancer: A retrospective experience. J Clin Oncol. 2012;30:(suppl; abstr e14614).
12. Vaccaro V, Bria E, Sperduti I, et al. Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice. J Clin Oncol. 2012;30:(suppl; abstr e14661).
13. Burris HR, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
14. O'Rourke TJ, Brown TD, Havlin K, et al. Phase I clinical trial of gem-citabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer. 1994;30A:417-419.
15. Poplin EA, Corbett T, Flaherty L, et al. Difluorodeoxycytidine (dFd-C)Vgemcitabine: a phase I study. Invest New Drugs. 1992;10:165-170.
16. Pollera CF, Ceribelli A, Grecco M, et al. Prolonged infusion of gemci-tabine: a preliminary report of a phase I study. Ann Oncol. 1992; 3(suppl 5):52.
17. Poplin E, Feng Y, Berlin J, et al. Phase III, randomized study of gemci-tabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27:3778-3785.
18. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15: 2403-2413.
19. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
20. Riess H, Helm A, Niedergethmann M, et al. A Randomised, Prospective, Multicenter, Phase III Trial of Gemcitabine, 5-Fluorouracil (5-FU), Folinic Acid vs. Gemcitabine Alone in Patients with Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II:4009.
21. Herrmann R, Bodoky G, Ruhstaller B, et al. Gemcitabine plus capecita-bine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and The Central European Cooperative Oncology Group. J Clin Oncol. 2007;25:2212-2217.
22. Cunningham D, Chau I, Stocken C, et al. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513-5518.
23. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946-3952.
24. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509-3516.
25. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcita-bine results in no survival advantage compared with gemcitabine mono-therapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776-3783.
26. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first line treatment in patients with locally advanced or metastatic pancreatic cancer. Br J Cancer. 2006;95:587-592.
27. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24:4441-4447.
28. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of peme-trexed plus gemcitabine versus gemcitabine in patients with unresect-able or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639-1645.
29. Van Cutsem E, Van de Velde H, Karasek P, et al. Phase III trial of gem-citabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
30. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3296-3302.
31. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161-167.
32. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
33. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizu-mab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol. 2010;28:3617-3622.
34. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gem-citabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed inter-group trial S0205. J Clin Oncol. 2010;28:3605-3610.
35. Shapiro J, Marshall J, Karasek P, et al. G17DT+Gemcitabine [Gem] versus Placebo+Gem in Untreated Subjects with Locally Advanced, Recurrent, or Metastatic Adenocarcinoma of The Pancreas: Results of A Randomized, Double-Blind, Multinational, Multicenter Study. Journal of Clinical Oncology. 2005 ASCO Annual Meeting Proceedings. Vol. 23, No. 16S: 4012.
36. Dose Escalation to Rash for Erlotinib Plus Gemcitabine in Patients with Metastatic Pancreatic Cancer: The Phase II RACHEL (BO21128) Study. ESMO 14th World Congress on Gastrointestinal Cancer, June 27-30, 2012, Barcelona, Spain. Abstract o-0006.
37. Exploratory Serum Biomarker Analyses From BO21129, A Phase II Study of Erlotinib in Second-Line Pancreatic Cancer: Potential Role of Amphiregulin? ESMO 14th World Congress on Gastrointestinal Cancer, June 27-30, 2012, Barcelona, Spain. Abstract o-0007.
38. Kindler HL, Gangadhar T, Karrison T, et al. Final analysis of a randomized phase II study of bevacizumab (B) and gemcitabine (G) plus cetux-imab (C) or erlotinib (E) in patients (pts) with advanced pancreatic cancer (PC). J Clin Oncol. 2008;26:abstract 4502.
39. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bev-acizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27:2231-2237.
40. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res. 2006;66:3928-3935.
41. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equili-brative nucleoside transporter-1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res. 2004;10:6956-6961.
42. Boeck SH, Raponi M, Richardson W, et al. Development of the SP120 rabbit monoclonal antibody for determining hENT1 status and predicting response to gemcitabine in pancreatic ductal adenocarcinoma. J Clin Oncol. 2012;30:(suppl; abstr 4041).
43. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adeno-carcinoma. J Clin Oncol. 2007;25:319-325.
44. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial JCO. 2011;29:4548-4554.
45. Reni M, Cereda S, Milella M, et al. Maintenance sunitinib (MS) or observation (O) in metastatic pancreatic adenocarcinoma (MPA): clinical and translational results of a phase II randomized trial. J Clin Oncol. 2012;30:(suppl, abstr 4017).
46. Gotfried J, Kozuch P. Long-term survival in patients with initial lung-only metastasis from pancreatic adenocarcinoma. J Gastrointest Cancer. 2012;43(suppl):50-55.
47. Arnaoutakis GJ, Rangachari D, Laheru DA, et al. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011;15:1611-1617.
48. Silva MJ, Maia JM, Ribeiro AR, et al. Beneficial trends of second-line chemotherapy in advanced pancreatic cancer. J Clin Oncol. 2012;30: (suppl; abstr e14680).
49. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplat-in for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902-910.
50. Boeck S, Heinemann V. Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer. J Clin Oncol. 2008;26:1178-1179; author reply 1179.
51. Assaf E, Verlinde-Carvalho M, Delbaldo C, et al. 5-fluorouracil/leucov- orin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic ad-enocarcinoma. Oncology. 2011;80:301-306.
52. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol. 2008;26:A4058.
53. Pelzer U, Schwaner I, Stieler J, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47:1676-1681.
54. Xiong HQ, Varadhachary GR, Blais JC, et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008;113:2046-2052.
55. Ghosn M, Farhat F, Kattan J, et al. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer. Am J Clin Oncol. 2007;30:15-20.
56. Gebbia V, Maiello E, Giulani F, et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Onco-logico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol. 2007;18(suppl 6):vi124-vi127.
57. Berk V, Ozdemir N, Ozkan M, et al. XELOX versus FOLFOX4 as second line chemotherapy in advanced pancreatic cancer. Hepatogas-troenterology. 2012;59.
58. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg. 1995;80: 290-295.
59. Wong GY, Schroeder DR, Carns PE, et al. Effect of neurolytic celiac plexus block on pain relief, quality of life, and survival in patients with unresectable pancreatic cancer. JAMA. 2004;291:1092-1099.
60. Bruno MJ, Haverkort EB, Tijssen GP, et al. Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with un-resectable cancer of the pancreatic head region. Gut. 1998;42:92-96.
61. Chabot JA, Tsai WY, Fine RL, et al. Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer. J Clin Oncol. 2010;28:2058-2063.
62. Dobrila DR, Guina T, Krznaric Z. Nutritional and pharmacologic support in patients with pancreatic cancer. Coll Anthropol. 2008;32:505-508.
63. Pelzer U, Arnold D, Goevercin M, et al. Parenteral nutrition support for patients with pancreatic cancer. Results of a phase II study. BMC Cancer. 2010:10:86.
64. Gonçalves A, Gilabert M, François E, et al. BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol. 2012: July 12, Epub ahead of print.